+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Early Phase 1
Age: 25Years - 65Years
All Genders
ID06899594

Pilot Study of Oral Psilocybin to Support Methamphetamine Abstinence in Adults Aged 25 to 65 in North Louisiana

Led by Kevin Murnane · Updated on 2025-10-07

20

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating whether a single 25 mg dose of psilocybin can help people who use methamphetamine achieve abstinence, while assessing how well this treatment is tolerated. The study focuses on individuals in Northern Louisiana currently receiving treatment for methamphetamine dependence. It aims to measure effects on methamphetamine abstinence, cravings, mood, cognitive function, and quality of life, as well as the nature of the psilocybin experience itself, including any challenging experiences and lasting effects. Participants will receive one oral dose of 25 mg psilocybin in a monitored session lasting 6 to 8 hours. Before this, they will attend 10 to 12 study visits over six months, including screening, baseline assessments, and three preparatory sessions two via telehealth and one in person to build trust and prepare for the psilocybin experience. After the dose, participants have two telehealth integration sessions to discuss insights and challenges, followed by follow-up assessments at 30, 60, and 120 days, with the final visit including a urine drug test. During the psilocybin session, vital signs like heart rate and blood pressure will be closely monitored. Participants will complete questionnaires about their experience after the session. Throughout the study, researchers will track retention rates, methamphetamine abstinence, physiological responses, and psychological effects. Participants will also undergo safety lab tests and clinical interviews to ensure well-being. The total study participation lasts up to six months, with both in-person and telehealth visits supporting ongoing assessment and care.

CONDITIONS

Brief Title

Psilocybin for Methamphetamine Addiction

Research Team

K

Kevin S Murnane, PhD

J

John A Vanchiere, MD, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here